netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Activa found 19 matches

Formulary items 4 matches
Sub Section Title / notes 1 match
   
Open monograph to display formulary status BNF Category
  Activa® hosiery Wound Care - Graduated compression hosiery - 18.09.01
  Activated charcoal  (Actidose Aqua Advance®, Carbomix®) Emergency Treatment of Poisoning - Pesticides - 16
  Poliomyelitis Vaccine InActivated (Salk)
(InActivated poliomyelitis vaccine (IPV)) 		Immunological products and vaccines - Poliomyelitis vaccines - 14.04
  Actisorb Silver 220 Wound Care - With charcoal - 18.03.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Letter sent to healthcare professionals (Nov 2016): lenalidomide (Revlimid▼): new advice about viral reactivation (08.02.04)
link in drug section Letter sent to healthcare professionals in June 2016: Thalidomide Celgene®: New important advice regarding viral reactivation and pulmonary hypertension (08.02.04)
link in drug section MHRA Drug Safety Update (Aug 2019): Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus (08.01.05)
link in drug section MHRA Drug Safety Update (August 2017): Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections (08.01.05)
link in drug section MHRA Drug Safety Update (Dec 2019): Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus (08.01.05)
link in subsection MHRA Drug Safety Update (Jan 2017): Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation (05.03.03.02)
link in drug section MHRA Drug Safety Update (Jan 2019): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (08.01.05)
link in drug section MHRA Drug Safety Update (July 2017): Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation (08.01.01)
link in drug section MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (08.01.05)
link in drug section MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (08.01.05)
link in drug section MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (08.01.05)
link in drug section MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (08.01.05)
link in drug section MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (08.01.05)
link in drug section MHRA Drug Safety Update (Oct 2019): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (08.01.05)

SubSection Titles / notes  
Nitrates, calcium-channel blockers, and potassium-channel Activators - (02.06)

 
netFormulary